NCT01125696View on ClinicalTrials.gov

Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2018

Study Completion Date

August 31, 2018

Conditions
HIVHepatitis B
Interventions
DRUG

Tenofovir/lamivudine/lopinavir-ritonavir

Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350

DRUG

Zidovudine/lamivudine/lopinavir-ritonavir

Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350

Trial Locations (2)

Unknown

Liuzhou MCH Hospital, Liuzhou

Guangxi MCH Hospital, Nanning

All Listed Sponsors
collaborator

National Center for AIDS/STD Control and Prevention, China CDC

OTHER_GOV

lead

Centers for Disease Control and Prevention

FED

NCT01125696 - Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV | Biotech Hunter | Biotech Hunter